Drug Trial Radar · NCT04164901
Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)
Last checked: Nov 19, 2026Latest source record: Apr 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
331
Actual
Start
Jan 5, 2020
Primary completion
Sep 6, 2022
Study completion May 2028
Sponsor
- Lead sponsor
- Institut de Recherches Internationales ServierAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 15, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study AG881-C-004 is a phase 3, multicenter, randomized, double-blind, placebo-controlled study comparing the efficacy of vorasidenib to placebo in participants with residual or recurrent Grade 2 glioma with an IDH1 or IDH2 mutation who have undergone surgery as their only treatment. Participants will be required to have central confirmation of IDH mutation status prior to randomization. Approximately 340 participants are planned to be randomized 1:1 to receive orally administered vorasidenib 40 mg QD or placebo.
Conditions
- Grade 2 Glioma
- Residual Glioma
- Recurrent Glioma
Interventions
VorasidenibDrug
Vorasidenib oral film-coated tablets
Matching PlaceboDrug
Matching Placebo oral tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS)Time frame: Up to approximately 30 months
Locations
84 sites in 11 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
City of Hope
Duarte, California
University of California San Diego
La Jolla, California
UCLA Oncology Center
Los Angeles, California
University of California Irvine - Hospital
Orange, California
University of California San Francisco
San Francisco, California
Stanford Cancer Center
Stanford, California
University of Colorado Hospital - Anschutz Cancer Pavilion
Aurora, Colorado
Yale University, Yale Cancer Center
New Haven, Connecticut
Mayo Clinic Jacksonville
Jacksonville, Florida
Sylvester Comprehensive Cancer Center - University of Miami Hospital and Clinics
Miami, Florida
Northwestern University
Chicago, Illinois
University of Chicago
Chicago, Illinois
Indiana University Medical Center
Indianapolis, Indiana
University of Kansas Medical Center
Kansas City, Kansas
University of Kentucky
Lexington, Kentucky
Maine Medical Partners Neurology
Scarborough, Maine
John Hopkins Cancer Center
Baltimore, Maryland
Tufts Medical Center
Boston, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan
Henry Ford Hospital
Detroit, Michigan
Metro Minnesota Community Oncology
Minneapolis, Minnesota
Mayo Comprehensive Cancer
Rochester, Minnesota
Washington University School of Medicine
St Louis, Missouri
Columbia University Medical Center
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Duke University Medical Center
Durham, North Carolina
Ohio State University Comprehensive Cancer Center
Columbus, Ohio
Oregon Health and Science University
Portland, Oregon
University of Pennsylvania
Philadelphia, Pennsylvania
University of Pittsburgh Hillman Cancer Center
Pittsburgh, Pennsylvania
Medical University of South Carolina
Charleston, South Carolina
Tennessee Oncology
Nashville, Tennessee
Baylor University Medical Center
Dallas, Texas
University of Texas Southwestern Medical Center
Dallas, Texas
MD Anderson Cancer Center
Houston, Texas
The University of Utah, Huntsman Cancer Hospital
Salt Lake City, Utah
Seattle Cancer Care Alliance
Seattle, Washington
Showing 40 of 84 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.